![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CTNND2 |
Gene summary for CTNND2 |
![]() |
Gene information | Species | Human | Gene symbol | CTNND2 | Gene ID | 1501 |
Gene name | catenin delta 2 | |
Gene Alias | GT24 | |
Cytomap | 5p15.2 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | E7EPC8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1501 | CTNND2 | HTA12-16-5 | Human | Pancreas | PDAC | 1.94e-02 | 5.85e-01 | 0.047 |
1501 | CTNND2 | HTA12-23-1 | Human | Pancreas | PDAC | 2.89e-11 | 1.17e+00 | 0.3405 |
1501 | CTNND2 | HTA12-25-1 | Human | Pancreas | PDAC | 8.73e-04 | 6.47e-01 | 0.313 |
1501 | CTNND2 | HTA12-26-1 | Human | Pancreas | PDAC | 9.82e-11 | 7.66e-01 | 0.3728 |
1501 | CTNND2 | HTA12-29-1 | Human | Pancreas | PDAC | 5.71e-55 | 1.18e+00 | 0.3722 |
1501 | CTNND2 | HTA12-32-1 | Human | Pancreas | PDAC | 5.30e-06 | 1.32e+00 | 0.3624 |
1501 | CTNND2 | P1_S1_AK | Human | Skin | AK | 8.79e-12 | 3.71e-01 | -0.3399 |
1501 | CTNND2 | P2_S3_AK | Human | Skin | AK | 7.41e-14 | 4.34e-01 | -0.3287 |
1501 | CTNND2 | P2_S4_SCCIS | Human | Skin | SCCIS | 4.43e-05 | 2.47e-01 | -0.3043 |
1501 | CTNND2 | P3_S6_AK | Human | Skin | AK | 2.08e-05 | 2.58e-01 | -0.3256 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Skin | ![]() | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma | ||
SCCIS:squamous cell carcinoma in situ |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605518 | Skin | AK | Wnt signaling pathway | 98/1910 | 444/18723 | 9.39e-14 | 3.09e-11 | 98 |
GO:019873818 | Skin | AK | cell-cell signaling by wnt | 98/1910 | 446/18723 | 1.26e-13 | 3.72e-11 | 98 |
GO:003011118 | Skin | AK | regulation of Wnt signaling pathway | 73/1910 | 328/18723 | 9.27e-11 | 1.52e-08 | 73 |
GO:003432919 | Skin | AK | cell junction assembly | 86/1910 | 420/18723 | 1.95e-10 | 2.68e-08 | 86 |
GO:004521626 | Skin | AK | cell-cell junction organization | 51/1910 | 200/18723 | 4.51e-10 | 5.24e-08 | 51 |
GO:006007017 | Skin | AK | canonical Wnt signaling pathway | 67/1910 | 303/18723 | 7.30e-10 | 7.45e-08 | 67 |
GO:006082818 | Skin | AK | regulation of canonical Wnt signaling pathway | 57/1910 | 253/18723 | 6.57e-09 | 4.47e-07 | 57 |
GO:000704319 | Skin | AK | cell-cell junction assembly | 36/1910 | 146/18723 | 3.88e-07 | 1.47e-05 | 36 |
GO:00609968 | Skin | AK | dendritic spine development | 27/1910 | 99/18723 | 1.34e-06 | 4.15e-05 | 27 |
GO:001635817 | Skin | AK | dendrite development | 49/1910 | 243/18723 | 2.42e-06 | 6.72e-05 | 49 |
GO:00508088 | Skin | AK | synapse organization | 71/1910 | 426/18723 | 2.21e-05 | 4.07e-04 | 71 |
GO:010602710 | Skin | AK | neuron projection organization | 23/1910 | 93/18723 | 4.44e-05 | 7.03e-04 | 23 |
GO:00970619 | Skin | AK | dendritic spine organization | 21/1910 | 84/18723 | 7.93e-05 | 1.09e-03 | 21 |
GO:00609975 | Skin | AK | dendritic spine morphogenesis | 17/1910 | 61/18723 | 8.79e-05 | 1.20e-03 | 17 |
GO:00488138 | Skin | AK | dendrite morphogenesis | 30/1910 | 146/18723 | 1.44e-04 | 1.73e-03 | 30 |
GO:00991737 | Skin | AK | postsynapse organization | 32/1910 | 168/18723 | 3.77e-04 | 3.65e-03 | 32 |
GO:0034329110 | Skin | SCCIS | cell junction assembly | 52/919 | 420/18723 | 7.89e-10 | 5.23e-07 | 52 |
GO:001635818 | Skin | SCCIS | dendrite development | 36/919 | 243/18723 | 3.00e-09 | 1.45e-06 | 36 |
GO:001605519 | Skin | SCCIS | Wnt signaling pathway | 51/919 | 444/18723 | 1.48e-08 | 4.37e-06 | 51 |
GO:019873819 | Skin | SCCIS | cell-cell signaling by wnt | 51/919 | 446/18723 | 1.72e-08 | 4.81e-06 | 51 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTNND2 | SNV | Missense_Mutation | c.2044N>A | p.Leu682Met | p.L682M | Q9UQB3 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-95-A4VK-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
CTNND2 | SNV | Missense_Mutation | novel | c.62N>A | p.Pro21His | p.P21H | Q9UQB3 | protein_coding | deleterious(0) | possibly_damaging(0.635) | TCGA-99-7458-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | tarceva | SD |
CTNND2 | SNV | Missense_Mutation | novel | c.272N>T | p.Ser91Ile | p.S91I | Q9UQB3 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-MN-A4N1-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CTNND2 | SNV | Missense_Mutation | novel | c.347A>T | p.Glu116Val | p.E116V | Q9UQB3 | protein_coding | deleterious(0.02) | probably_damaging(0.977) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CTNND2 | SNV | Missense_Mutation | c.1715N>G | p.Ala572Gly | p.A572G | Q9UQB3 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-MP-A4T6-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
CTNND2 | SNV | Missense_Mutation | c.2188N>A | p.Arg730Ser | p.R730S | Q9UQB3 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-MP-A4TC-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
CTNND2 | SNV | Missense_Mutation | c.386N>A | p.Arg129Lys | p.R129K | Q9UQB3 | protein_coding | deleterious(0.03) | possibly_damaging(0.867) | TCGA-MP-A4TF-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | navelbine | PD | |
CTNND2 | SNV | Missense_Mutation | c.2561N>C | p.Leu854Pro | p.L854P | Q9UQB3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MP-A4TK-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
CTNND2 | SNV | Missense_Mutation | novel | c.2105N>T | p.Arg702Leu | p.R702L | Q9UQB3 | protein_coding | deleterious(0.02) | benign(0.131) | TCGA-NJ-A4YF-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTNND2 | SNV | Missense_Mutation | c.3394G>T | p.Ala1132Ser | p.A1132S | Q9UQB3 | protein_coding | tolerated(0.76) | benign(0.003) | TCGA-NJ-A4YI-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |